Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seaport Therapeutics, Inc. - Common Stock (NQ:SPTX)

18.15 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 18.15
Bid (Size) 8.070 (100)
Ask (Size) 21.48 (100)
Prev. Close 18.15
Today's Range 18.15 - 18.15
52wk Range 14.85 - 28.38
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
From PureTech Health plc
Via Business Wire
News headline image
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
From Seaport Therapeutics, Inc.
Via Business Wire

Performance

52-Week Range 36.1% below 52-week high
18.15
14.8552W Low 28.3852W High
1 Week 4.7% below 1-week high
17.071W Low 19.051W High

Seaport Therapeutics, Inc. - Common Stock (SPTX) traded between $14.85 and $28.38 over the past 52 weeks and last traded at $18.15, 36.1% below its 52-week high. Over the past week it ranged between $17.07 and $19.05.

Past 12 Months
-1.9%
-22.2%
-9.7%
-8.5%
-8.5%
-8.5%
1W -$0.35
1M -$5.19
3M -$1.95
6M -$1.69
YTD -$1.69
1Y -$1.69

SPTX was -8.5% over the past year, -8.5% over six months, -8.5% year to date, -1.9% in the last week.

12 Months vs Market
SPTX
-8.5%
DIA
+12.0%
SPY
+17.4%
QQQ
+24.8%
IWM
+14.1%

Over the past 12 months SPTX returned -8.5% versus DIA (Dow) +12.0%, SPY (S&P 500) +17.4%, QQQ (Nasdaq 100) +24.8% and IWM (Russell 2000) +14.1%.

Volume & Liquidity
1W
202.7K
1M
314.8K
3M
183.9K
6M
265.3K
YTD
265.3K
1Y
265.3K

SPTX's 3-month average daily volume is 183.9K.

More News

Read More
News headline image
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
From PureTech Health plc
Via Business Wire
News headline image
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
From Seaport Therapeutics, Inc.
Via Business Wire
News headline image
Seaport Therapeutics to Participate in September Investor Conferences
From Seaport Therapeutics, Inc.
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
From PureTech Health plc
Via Business Wire
News headline image
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
From Seaport Therapeutics, Inc.
Via Business Wire
News headline image
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
From Seaport Therapeutics, Inc.
Via Business Wire
News headline image
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
From Seaport Therapeutics, Inc.
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
From PureTech Health plc
Via Business Wire
News headline image
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
From Seaport Therapeutics, Inc.
Via Business Wire
News headline image
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
From Seaport Therapeutics, Inc.
Via Business Wire
News headline image
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
From Seaport Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Seaport Therapeutics, Inc. - Common Stock publicly traded?
Yes, Seaport Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Seaport Therapeutics, Inc. - Common Stock trade on?
Seaport Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Seaport Therapeutics, Inc. - Common Stock?
The ticker symbol for Seaport Therapeutics, Inc. - Common Stock is SPTX on the Nasdaq Stock Market
What is the current price of Seaport Therapeutics, Inc. - Common Stock?
The current price of Seaport Therapeutics, Inc. - Common Stock is 18.15
When was Seaport Therapeutics, Inc. - Common Stock last traded?
The last trade of Seaport Therapeutics, Inc. - Common Stock was at 10/09/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.